Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol UBE2I contributors: mct/npt/pgu - updated : 08-04-2016
HGNC name ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast)
HGNC id 12485
Type ubiquitous
   expressed in (based on citations)
SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
 stomach   highly
Endocrinethyroid   highly
Lymphoid/Immunelymph node   highly
Reproductivefemale systemovary  highly
Visualeye     Homo sapiens
SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
Connectiveadipose    Homo sapiensAdult
SystemCellPubmedSpeciesStageRna symbol
not specificadipocyte Homo sapiensAdult
cell lineage
cell lines
physiological period pregnancy
Text placenta
  • conserved UBC domain of 150 AA harboring the cysteine residue required for enzyme-ubiquitin thioester formation
  • C-terminus involved in both the protein-protein interaction and its sumoylation-modifying activity provide the mechanism for regulating nuclear receptor functions
    interspecies homolog to yeast UBC9
    homolog to S.Cerevisiae Scubc9
  • ubiquitin-conjugating enzyme family
  • CATEGORY enzyme
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,nucleus,nucleoplasm,nuclear bodies,nuclear speckles
  • strikingly colocalized with SFRS2, which is a component of nuclear speckles and critical for mRNA processing
  • expressed predominantly in the nucleus of preadipocytes but shifted to cytoplasmic compartments
  • SAE1, UBE2I and PIAS1 are distributed in both nucleus and cytoplasm of ocular cell lines
  • basic FUNCTION
  • involved in ubiquitin conjugation,second step of ubiquitin-dependent proteolysis
  • SUMO-E2 enzyme, sufficient for substrate recognition and lysine modifications of SUMO targets
  • promoting nuclear accumulation and metabolic stability of tumor suppressor SMAD4
  • can function as a co-factor of PLAGL2, uncoupling from its enzymatic activity, to mediate PLAGL2 interactive surfactant protein-C promoter activity
  • essential gene which is required for cell cycle progression and is involved in the degradation of S phase and M phase cyclins
  • sufficient for substrate recognition and lysine modification of known SUMO targets
  • essential protein in mammalian cells with a predominantly nuclear localization
  • critical for mRNA processing, and having a possible function of sumoylation in gene expression
  • E2-conjugating enzyme that transfers the activated small ubiquitin-like modifier (SUMO) to protein substrates, and thus it has an important function in sumoylation-mediated cellular pathways
  • involved in protein modification through covalent attachment of small ubiquitin-like modifier and, has emerged as a key regulator of cell proliferation and differentiation
  • appears to play an important role in adipogenesis
  • negatively regulates osteoblastic differentiation induced by BMP via, at least in part, SUMOylation of SMAD4
  • UBE2I acts as a functional binding partner of FYB1 and plays a selective role in integrin-mediated T cell adhesion via modulation of RAP1A-RASSF5 membrane recruitment and RAC1 activation
  • CELLULAR PROCESS cell cycle
    nucleotide, repair
    protein, degradation
    a component
  • UBE2I associated to FHIT
  • RANBP2 forms a stable complex with SUMO-modified RANGAP1 and UBE2I at the nuclear pore complex
  • member of the surfactant protein-C promoter complex
  • IPO13ľUBE2I9 complex forms in the cytosol and translocates into the nucleus
  • non-covalent ternary complex formed by PIAS1, SUMO1, and UBE2I proteins involved in transcriptional regulation
    small molecule
  • associating with RAD51, RAD52 proteins in the double strand RAD51/RAD52 repair pathway
  • associating with UBL1 and TP53, involved in DNA recombination and essential for cell-cycle progression
  • associating with FHIT for cell-cycle control
  • interacting with ETV6 leading to sumoylation of ETV6 (TEL) by UBL (SUMO-1)
  • interacted with the DNA-binding and ligand-binding domains of ESR1
  • protein interacting with UIMC1
  • interacted with SOX4 through HMG-box domain of SOX4 and represses its transcriptional activity independent of its SUMO-1-conjugating activity
  • interacting with STAR and FOXL2 (UBE2I-mediated sumoylation at lysine 25 of FOXL2 is required for transcriptional repression of the STAR gene and may be responsible for controlling the development of ovarian follicles)
  • ZMYND11 interacts with PIAS1 (a well-characterized SUMO E3 enzyme) and UBE2I (the only SUMO E2 enzyme so far identified) through its distinct regions
  • molecular link between UBE2I and the metastasis genes such as CDC42 and CXCR4, and thus provide new insight into the mechanism by which UBE2I9 promotes tumor invasion and metastasis
  • binding of BRCA1 proteins to nuclear chaperone UE2I provides a novel mechanism for nuclear import and control of tumor growth
  • is an interaction partner of the transcription factor EGR2, a key regulator of hindbrain development
  • SETD8 interacts with the UBE2I E2 SUMO conjugating enzyme (directly binds SETD8 proximal to the catalytic SET domain)
  • RANBP2 forms a stable complex with SUMO-modified RANGAP1 and UBE2I at the nuclear pore complex
  • SKI can enhance UBE2I-mediated cellular sumoylation, possibly through direct interaction with UBE2I
  • interaction between the CANX cytoplasmic domain and UBE2I, a SUMOylation E2 ligase, which modified the calnexin cytoplasmic domain by the addition of SUMO
  • UBE2I interacted directly with FYB1 and the association was increased in response to anti-CD3 stimulation
  • cell & other
    Other autosumoylation of the mammalian E2-conjugating enzyme UBE2I at Lys14 regulates target discrimination
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in advanced melanomas
    Susceptibility to late-onset Alzheimer disease (AD)
    Variant & Polymorphism other UBE2I polymorphisms might be associated with a risk of AD
    Candidate gene
    Therapy target
    blocking expression of UBE2I sensitizes melanomas to the cytotoxic effects of chemotherapeutic drugs